Details

Autor(en) / Beteiligte

• Zhang, Ya‐Ping
• Yang, Xi
• Lin, Zeng‐Hua
• Wang, Xin‐Feng
• Cao, Xin
• You, Xue‐Fen
• Huang, Hong‐Ming
• Shi, Wen‐Yu
• Liu, Hong

Titel

Low‐dose bortezomib and dexamethasone as primary therapy in elderly patients with Waldenstrӧm macroglobulinemia

Ist Teil von

• European journal of haematology, 2017-12, Vol.99 (6), p.489-494

Ort / Verlag

England

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective This retrospective study was designed to determine the efficacy and safety of low‐dose bortezomib and dexamethasone (lBD) in elderly Chinese patients with Waldenstrӧm macroglobulinemia (WM). Methods Ten patients with WM aged over 60 years received first‐line treatment with lBD. Results The median age was 70 years (range, 61‐77 years). The overall response rate was 80%, including 1 patient who achieved a complete response, 1 patient with very good partial response, and 6 patients with a partial response. Median time to response was 1.8 months after treatment with lBD. Six (60%) patients achieved a partial response, including 2 (20%) patients who had a more than 75% reduction in serum immunoglobulin M levels. A rapid reduction in paraprotein was observed in three patients who received plasmapheresis. After a median follow‐up period of 36 months, all patients were still alive and six had no disease progression. The estimated median time to progression was 39 months (range, 15‐60 months). The most common adverse events were anemia, thrombocytopenia, neuropathy, and neutropenia. Peripheral neuropathy was the most common non‐hematological toxicity in six (60%) patients, but did not result in the discontinuation of bortezomib. Conclusions Our findings show that lBD is an effective and tolerable treatment regimen for elderly patients with WM.